Preparation and application of liver cancer radiofrequency ablation curative effect enhancer taking MELK as target
By using siRNA and lipid nanoparticles to target MELK particles in liver cancer cells, the problem of insufficient targeting MELK inhibitors in the prior art was solved, and more efficient hepatitis cancer treatment effect was achieved, especially after radiofrequency ablation of tumors Cell inhibition and immune activation.
Patent Information
- Application Number
- CN202410977575.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-22
AI Technical Summary
The existing MELK inhibitors lack targeting and are difficult to effectively target tumor cells, resulting in poor radiofrequency ablation of liver cancer, and instability of siRNA and difficulty reaching the tumor site.
Targeted MELK particles containing siRNA and lipid nanoparticles (LNPs) were developed to enhance the tumor targeting and release efficiency of siRNA using RGD peptide and pH response signals, and improve the inhibitory effect of MELK mRNA.
It significantly improves the inhibition rate and tumor targeting of the MELK gene, enhances the sensitivity of liver cancer cells to radiofrequency ablation, and the efficacy is significantly improved when combined with radiofrequency ablation.
Smart Images

Figure BDA0004955029740000121 
Figure BDA0004955029740000131 
Figure HDA0004955029810000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of anti-tumor drugs, and relates to a MELK mRNA inhibitor targeting a tumor after radiofrequency ablation of liver cancer with MELK activation mutation. Background Art
[0002] Liver cancer is a common and fatal malignant tumor worldwide. Radiofrequency ablation (RFA) is an important means of local treatment of liver cancer. Its principle is to quickly increase the temperature in the tissue in a short period of time by placing electrodes on the tumor tissue, thereby inducing massive coagulative necrosis of tumor cells. At the same time, RFA can also activate tumor immunity and further play a tumor cell killing role. However, the scope of RFA's direct tumor cell necrosis in tumors is limited. The existence of the "heat drop effect" and the short duration of activation of specific immune responses are key limiting factors that affect the efficacy of RFA and easily lead to recurrence and progression of residual cancer.
[0003] MELK is a member of the AMPK kinase family. It affects phosphorylation by directly and indirectly binding to other proteins, mediates signal transduction at all levels of cells, and participates in regulating tumor cell proliferation, apoptosis, invasion and migration. Previous reports have confirmed that MELK is associated with the recurrence of early liver cancer. Inhibiting MELK expression can inhibit the growth and tumor formation of liver cancer cells by inducing apoptosis of liver cancer cells and inhibiting cell mitosis. High expression of MELK is positively correlated with poor prognosis of liver cancer patients. In addition, previous studies have found that MELK is a potential target affecting the RFA effect of liver cancer. Knocking down MELK not only inhibits the growth and metastasis of liver cancer, but also enhances the efficacy of radiofrequency ablation of liver cancer. It can also inhibit the progression of liver cancer by inhibiting the polarization of tumor-associated macrophages M2 and promoting M1 polarization and CD8+T cell infiltration.
[0004] When MELK knockdown is combined with RFA for liver cancer, the efficacy of RFA for liver cancer is further increased by amplifying RFA-related tumor macrophage polarization and CD8+T cell recruitment. The development of new drugs and intervention methods targeting MELK mRNA is a new research direction to improve the therapeutic effect of liver cancer. Currently, MELK inhibitors mainly target its kinase activity and lack specific cell targeting. Using siRNA to target MELK mRNA is the main method to inhibit MELK expression. However, naked siRNA is unstable and easily degraded by enzymes in the blood or phagocytosed by phagocytes in organs, making it difficult for them to reach the tumor site.
[0005] In view of this, there is still a need in the art for a method and a drug that effectively targets MELK, so that it has higher tumor targeting and longer efficacy, and can be used in combination with RFA. Summary of the invention
[0006] According to one aspect of the present disclosure, a particle targeting MELK is provided, comprising siRNA and lipid nanoparticles (LNP).
[0007] Target refers to the object targeted by the particle of the present disclosure or the siRNA of the present disclosure. The target can be a nucleic acid (gene, mRNA, etc.) or a protein (precursor, mature protein, isoform, variant, etc.). In the present disclosure, the target particularly refers to the MELK gene or its expression product.
[0008] MELK in the present disclosure should be interpreted broadly, referring to the MELK gene itself and its various forms of expression products at various stages, such as but not limited to molecules produced during gene amplification, replication, transcription, splicing, processing, translation, and modification, such as cDNA, mRNA, precursor protein, mature protein, natural variants, modified forms, and fragments thereof.
[0009] In the present disclosure, MELK is MELK of Homo sapiens.
[0010] As a specific example, the target in the present disclosure is MELK mRNA.
[0011] The nucleotide or amino acid information of MELK is well known in the art, and can be obtained from documents or databases, for example but not limited thereto. The technician should understand that, although the specific accession number of MELK is given in the database, MELK is not limited to the number in a specific database, and is also intended to cover equivalent references in any document, book, or database in the prior art.
[0012] In some embodiments, the siRNA targets any target site in the MELK mRNA that is 17 to 25 consecutive nucleotides long.
[0013] In some embodiments, the siRNA targets any target site in MELK mRNA that is at least 21 nucleotides long (eg, 21, 22, 23, 24, 25, 26, etc.).
[0014] In specific embodiments, the antisense strand of the siRNA is allowed to have no more than 3, no more than 2, or no more than 1 mismatch with the target.
[0015] In specific embodiments, the sense strand of the siRNA is allowed to differ from the target by no more than 3, no more than 2, or no more than 1 nucleotide.
[0016] siRNA is a double-stranded polynucleotide. After siRNA is introduced into a cell, it interferes with or inhibits the expression or activity of a target in the cell. In the field of interference, siRNA is used to regulate (especially for interference, inhibition, silencing, inactivation in the present disclosure) the expression or activity of a target.
[0017] Although not limited to a specific theory, a representative working mode of siRNA is as follows: Dicer (a ribonuclease) cuts dsRNA into siRNA of about 19 to 23 nt, with two tt-consisting overhangs at its 3' end; siRNA then binds to the ribonuclease complex to form RISC (RNA-induced silencing complex); the complex depolymerizes siRNA into single strands to activate RISC; the activated RISC cuts the target transcript with a homologous sequence through the principle of complementary base pairing, ultimately leading to gene silencing.
[0018] In view of this, siRNAs (regardless of whether they have overhangs) should fall within the scope of the present disclosure.
[0019] As an example, siRNA targets and binds to complementary nucleotide sequences in target mRNA.
[0020] The present disclosure provides a siRNA, which comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a double-stranded region, and the sense strand and the antisense strand are at least partially reverse complementary.
[0021] The sense strand and the antisense strand are selected from any one of the following combinations:
[0022] The sense strand comprises at least 21 consecutive nucleotides that differ by no more than 3 nucleotides from the sequence shown in SEQ ID NO: 1 (5′-cagaaacaacaggcaaacaat-3′), and the antisense strand comprises at least 21 consecutive nucleotides that differ by no more than 3 nucleotides from the sequence shown in SEQ ID NO: 2 (5′-gcctgaaagaaactccaatta-3′); or
[0023] The sense strand comprises at least 21 consecutive nucleotides that differ by no more than 3 nucleotides from the sequence shown in SEQ ID NO: 3 (5′-gcagctcctgaactaatacaa-3′), and the antisense strand comprises at least 21 consecutive nucleotides that differ by no more than 3 nucleotides from the sequence shown in SEQ ID NO: 4 (5′-gctggattgatagactatgaa-3′).
[0024] The term "complementary" or "reverse complement" refers to the fact that in a double-stranded nucleic acid, the bases of one strand pair with bases on the other strand in a complementary manner. In RNA, adenine (A) pairs with uracil (U); cytosine (C) pairs with guanine (G). When adenine on one strand pairs with thymine (or uracil) on the other strand, and guanine always pairs with cytosine, the two strands are considered to be complementary to each other. The sequence of a strand can be inferred from the sequence of its complementary strand.
[0025] The term "at least partially reverse complementary" means that there are no more than 3 base mismatches between the two nucleotide sequences involved.
[0026] The term "completely complementary" refers to the absence of base mismatches between two nucleotide sequences.
[0027] The term "mismatch" means that in a double-stranded nucleic acid, the bases at corresponding positions are not paired in a complementary manner.
[0028] LNPs are lipid-based nanoparticles that are commonly used to deliver siRNA and can be enriched in tumor tissues through retention effects and active targeting.
[0029] In certain embodiments, the siRNA described in the present disclosure is encapsulated in lipid nanoparticles (LNPs). In certain embodiments, LNPs include one or more lipids, such as triglycerides (e.g., tristearin), diglycerides (e.g., behenyl glyceryl), monoglycerides (e.g., monostearin), fatty acids (e.g., stearic acid), steroids (e.g., cholesterol), and waxes (e.g., hexadecyl palmitate).
[0030] In some embodiments, the LNP comprises one or more cationic lipids and one or more helper lipids. In some embodiments, the LNP comprises one or more cationic lipids, cholesterol, and one or more neutral lipids.
[0031] Cationic lipids refer to any of a variety of lipids that have a net positive charge at a selected pH (e.g., physiological pH). Such lipids include, but are not limited to, 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLenDMA), dioctadecyldimethylammonium (DODMA), distearyldimethylammonium (DSDMA), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC); N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DDAC); Methylammonium chloride (DOTMA); N,N-distearyl-N,N-dimethylammonium bromide (DDAB); N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP); 3-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol) and N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE).
[0032] For example, cationic lipids with positive charge under conditions below physiological pH include but are not limited to DODAP, DODMA and DMDMA. In some embodiments, the cationic lipid comprises an ether bond between a C18 alkyl chain, a head group and the alkyl chain, and 0 to 3 double bonds. Such lipids include, for example, DSDMA, DLinDMA, DLenDMA and DODMA. Cationic lipids can include an ether bond and a pH titrable head group. Such lipids include, for example, DODMA.
[0033] In some embodiments, cationic lipids include protonatable tertiary amine head groups. Such lipids are referred to as ionizable lipids in the present disclosure. Ionizable lipids refer to lipid species that include ionizable amine head groups and typically include pKas less than about 7. Therefore, in an acidic pH environment, ionizable amine head groups are protonated so that ionizable lipids preferentially interact with negatively charged molecules (e.g., nucleic acids, such as siRNA described in the present disclosure), thereby promoting the assembly and encapsulation of nanoparticles. Therefore, in some embodiments, ionizable lipids can increase the load of nucleic acids in lipid nanoparticles. In an environment where the pH value is greater than about 7 (e.g., a physiological pH value of about 7.4), ionizable lipids include neutral charges. When particles comprising ionizable lipids are absorbed into the low pH environment of the endosome, ionizable lipids are protonated again and associate with anionic endosomal membranes, thereby promoting the release of the contents encapsulated by the particles. In some embodiments, the cationic lipid is an ionizable lipid selected from DLinDMA, DLin-KC2-DMA and DLin-MC3-DMA. In some embodiments, the cationic ionizable lipid is DLin-MC3-DMA (MC3).
[0034] In the LNPs disclosed herein, the pH response signal is used to provide pH-dependent siRNA release for the synthesized RGD LNPs. When the pH is 6.0, the cumulative release of siRNAs from RGD LNPs into the environment is significantly higher than the cumulative release at pH 7.4, resulting in a better release rate of siRNA in the tumor microenvironment.
[0035] In some embodiments, the LNP comprises one or more non-cationic helper lipids (neutral lipids). Exemplary neutral helper lipids include (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine) (DLPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DiPPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), (1,2-dioleoyl-sn-glycero-3-phospho-(l'-rac-glycerol) (DOPG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), ceramide, sphingomyelin and cholesterol.
[0036] In some embodiments, the lipid nanoparticle may further include one or more PEG-modified lipids, the lipids comprising a poly (ethylene) glycol chain up to 5 kDa covalently attached to a lipid comprising one or more C6-C20 alkyl groups. In some embodiments, LNP also includes 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-poly (ethylene glycol) (DSPE-PEG) or 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[amino (polyethylene glycol)] (DSPE-PEG-amine). In some embodiments, the PEG-modified lipid accounts for about 0.1% to about 1% of the total lipid content in the lipid nanoparticle. In some embodiments, the PEG-modified lipid accounts for about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9% or about 1.0% of the total lipid content in the lipid nanoparticle.
[0037] In some specific embodiments, LNP comprises a cationic lipid and one or more auxiliary lipids, wherein the cationic lipid is DOTAP. In some embodiments, LNP comprises a cationic lipid and one or more auxiliary lipids, wherein one or more auxiliary lipids comprise cholesterol. In some embodiments, LNP comprises a cationic lipid and one or more auxiliary lipids, wherein one or more auxiliary lipids comprise DPPC. In some embodiments, LNP comprises a cationic lipid and one or more PEG-modified lipids, wherein one or more PEG-modified lipids are DSPE-PEOz. In some embodiments, LNP comprises a cationic lipid and at least two auxiliary lipids, wherein the cationic lipid is DOTAP, and at least two auxiliary lipids include cholesterol and DPPC. In some embodiments, LNP comprises a cationic lipid, at least two auxiliary lipids and a PEG-modified lipid; wherein the cationic lipid is DOTAP, at least two auxiliary lipids include cholesterol and DPPC, and the PEG-modified lipid is DSPE-PEOz.
[0038] In some embodiments, the lipid nanoparticles are coated with an arginine-glycine-aspartic acid tripeptide (RGD peptide) (see Ruoslahti, Advanced Materials, 24, 2012, 3747-3756; and Bellis et al., Biomaterials, 32 (18), 2011, 4205-4210). In some embodiments, the RGD peptide is conjugated to the surface of the LNP. The RGD peptide is selected from the group consisting of cRGD, RGD-4C, iRGD, and RGD-PEG.
[0039] To facilitate the incorporation of RGD, in some embodiments, the LNP comprises a cationic lipid, at least two auxiliary lipids and a PEG-modified lipid, and a lipid carrying RGD; wherein the cationic lipid is DOTAP, the at least two auxiliary lipids include cholesterol and DPPC, the PEG-modified lipid is DSPE-PEOz, and the lipid carrying RGD is DSPE-PEG2K-cRGD.
[0040] In some specific embodiments, the LNP consists of DPPC, DOTAP, CHOL, DSPE-PEOz, DSPE-PEG2K-cRGD.
[0041] In some specific embodiments, the molar fraction of DPPC is 80 to 120 (such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120), preferably 100; the molar fraction of DOTAP is 40 to 60 (40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60), preferably 50; the molar fraction of CHOL is 40 to 60 (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60), preferably 50; the molar fraction of DSPE-PEOz is 16 to 24 (16, 17, 18, 19, 20, 21, 22, 23, 24), preferably 20; the molar fraction of DSPE-PEG2K-cRGD is 8 to 12 (such as 8, 9, 10, 11, 12), preferably 10.
[0042] It should be understood by the technician that the "molar fraction" here is a relative concept, not an absolute concept, and refers to the fraction of the compound relative to other components in LNP in terms of the molar number (i.e., the amount of substance) of the compound. Taking "the molar fraction of the DPPC is 80 to 120" as an example, it cannot be understood that the DPPC is 80 to 120 moles, but should be interpreted as compared with other components in LNP, when the molar fraction of the DPPC is 80 to 120, the molar fraction of the DOTAP is 40 to 60. In other words, the molar ratio of DPPC to DOTAP is between 4:3 and 3:1, regardless of the specific molar number. By analogy, when the molar fraction of the DOTAP is 40 to 60, the molar fraction of the CHOL is 40 to 60, then the molar ratio of the two is between 2:3 and 3:2.
[0043] In a specific embodiment, the molar ratio of DPPC, DOTAP, CHOL, DSPE-PEOz, and DSPE-PEG2K-cRGD is 2:1:1:0.4:0.2.
[0044] In some embodiments, the average size of the LNPs is from about 50 nm to about 300 nm. For example, in some embodiments, the average size of the LNPs is from about 50 nm to about 200 nm, from about 80 nm to about 200 nm, from about 80 nm to about 1500 nm, from about 80 nm to about 120 nm, from about 90 nm to about 110 nm, such as about 100 nm.
[0045] In some embodiments, the average zeta potential of the LNP is between 28 mV and 36 mV. In some specific embodiments, the average zeta potential of the LNP is about 30 mV, about 31 mV, about 32 mV, about 33 mV, about 34 mV.
[0046] In some embodiments, the lipid nanoparticles comprise the siRNA of the present disclosure, and the ratio of lipid (L) to nucleic acid (N) is about 10: 1 to 5: 1 (L: N) (by mass). In some specific embodiments, the lipid nanoparticles comprise the siRNA of the present disclosure, and the L: N ratio is preferably 8: 1.
[0047] In some embodiments, the particles targeting MELK further comprise near-infrared dyes, preferably cyanine dyes. The technician understands that the role of the dye is to facilitate detection, diagnosis, visualization, quantification, tracing, etc., which is not necessary. The technician can choose whether to introduce a dye according to the application purpose, which does not affect the targeting or inhibitory activity of the particles targeting MELK or siRNA.
[0048] In some embodiments, the cyanine dye is selected from Cy5.5, Cy7 and ICG.
[0049] In some embodiments, the mass percentage of the cyanine dye in the LNP is between 1% and 5%.
[0050] In some specific embodiments, the cyanine dye is Cy5.5.
[0051] In some specific embodiments, Cy5.5 is selected from: Cy5.5-NHS, Cy5.5-SE, preactivated PE-Cy5.5 maleimide, sulfo-Cyanine5.5 alkyne, sulfonated Cy5.5-azide; preferably Cy5.5-NHS.
[0052] The present disclosure also provides a pharmaceutical composition comprising:
[0053] 1) the aforementioned MELK-targeting particle; and
[0054] 2) Pharmaceutically acceptable carriers, diluents, and / or excipients.
[0055] The term "pharmaceutical composition" refers to a mixture containing one or more active ingredients (or their pharmaceutically acceptable salts) and other chemical components. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0056] "Pharmaceutically acceptable carriers" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, osmotic pressure regulator, isotonic agent, solvent or emulsifier approved by the Food and Drug Administration for human or animal use (e.g., Remington: The Science and Practice of Pharmacy 19th edition, 1995). As a non-limiting example, the pharmaceutically acceptable carrier is selected from any one or a combination of the following: saline solution, sugar solution, polymer, peptide (such as polypeptide), gel, micelle.
[0057] The active ingredients of the present disclosure may exist in the form of pharmaceutically acceptable salts thereof (selected from inorganic salts or organic salts).
[0058] In some embodiments, the disclosed MELK-targeted particles may be mixed with a pharmaceutically acceptable active or inert substance to prepare a pharmaceutical composition or formulation. The pharmaceutical composition and methods for preparing the pharmaceutical composition depend on a number of factors, including but not limited to the route of administration, the extent of the disease, or the dose to be administered.
[0059] In some embodiments, the pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier.
[0060] In some embodiments, the pharmaceutical composition comprises a sterile saline solution. In some embodiments, such a pharmaceutical composition consists of a sterile saline solution and particles targeting MELK. In some embodiments, the sterile saline is a pharmaceutical grade saline.
[0061] In some embodiments, the pharmaceutical composition comprises particles targeting MELK and sterile water; or consists of particles targeting MELK and sterile water. In some embodiments, the sterile water is pharmaceutical grade water. In some embodiments, the pharmaceutical composition comprises particles targeting MELK and phosphate buffered saline. In some embodiments, the pharmaceutical composition consists of particles targeting MELK and sterile buffer (such as PBS). In some embodiments, the sterile PBS is pharmaceutical grade PBS.
[0062] The stabilizer may be at least one of sorbitol, sucrose, trehalose, mannose, maltose, lactose, and glucose.
[0063] The osmotic pressure regulator can be sodium chloride and / or potassium chloride. The content of the osmotic pressure regulator makes the osmotic pressure of the pharmaceutical composition 200-700mOsm / kg. According to the required osmotic pressure, those skilled in the art can easily determine the content of the osmotic pressure regulator.
[0064] The pharmaceutical composition can be conveniently presented in unit dosage form. Generally, the pharmaceutical composition can be formulated into any suitable dosage form, such as but not limited to, injection, tablet, capsule, gel, etc. The pharmaceutical composition includes but is not limited to solution, emulsion, liposome-containing formulation.
[0065] In a non-limiting example, the MELK-targeting particles of the present disclosure dissolved in water for injection or saline are prepared in the form of a pre-filled syringe (subcutaneous injection type).
[0066] The present disclosure also provides a medicine box or a kit, which comprises one or more containers, wherein the containers independently comprise the MELK-targeting particle or pharmaceutical composition of the present disclosure.
[0067] The present disclosure provides a use of the above-mentioned MELK-targeting particle in preparing a drug for preventing / treating a disease in a subject. In some embodiments, the disease is a hepatic disease or a disease related to MELK gene expression.
[0068] In some embodiments, the disease associated with MELK gene expression is liver cancer.
[0069] Another aspect of the present disclosure provides a method for treating a disease in a subject, comprising administering to the subject an effective amount of the MELK-targeting particle or pharmaceutical composition of the present disclosure.
[0070] Another aspect of the present disclosure provides a method for inhibiting the expression of MELK mRNA in a subject, the method comprising administering to the subject an effective amount of the particle or pharmaceutical composition targeting MELK of the present disclosure.
[0071] "Effective amount" refers to the amount of a pharmaceutically active ingredient (such as the targeted particles disclosed herein) that induces a desired effect in a subject. In a specific embodiment, those skilled in the art can determine the selection of an effective amount based on consideration of a variety of factors (e.g., via clinical trials), including the disease to be treated, the symptoms involved, the route of administration, the severity of the disease, the patient's weight, the patient's immune status, and other factors known to those skilled in the art.
[0072] The effective amount in the specific embodiment can be obtained from the dose-response curve derived from the animal model test system, and it is allowed to be determined according to the judgment of the physician and the situation of each patient. Among them, the relationship between the dosage of animals and humans is described in Freireich et al. 1966, Cancer Chemother Rep 50:219, and the human body surface area can be approximately determined by the height and weight of the patient.
[0073] The amount of drug required for a single administration to a patient can be conveniently obtained by calculating the product of the patient's weight and the unit weight dose required for the patient's single administration. For example, in the process of preparing drugs, it is generally believed that the weight of an adult is 50-70 kg, and the dosage can be initially determined by the equivalent dose conversion relationship between the unit weight dose of experimental animals and humans. For example, it can be determined based on the guidance opinions put forward by drug administration agencies such as FDA and SFDA, or by reference to (Huang Jihan et al., "Conversion of equivalent doses between animals and between animals and humans in pharmacological experiments", "Chinese Journal of Clinical Pharmacology and Therapeutics", 2004 Sep; 9 (9): 1069-1072). In some embodiments, the dosage for humans and mice can be converted using a conversion coefficient of 0.0026 based on the body surface area of humans and mice.
[0074] Interfering with or inhibiting the expression or activity of a target in a cell refers to a reduction or blockade of the expression or activity relative to the expression or activity in an untreated or control sample, and should not be interpreted as the expression or activity being completely eliminated.
[0075] The MELK-targeting particles provided by the present disclosure show a good inhibitory effect on the MELK gene in hepatocytes. In some specific embodiments, the MELK-targeting particles provided by the present disclosure can significantly inhibit the expression of the MELK gene, and the inhibition rate can be as high as 80% to 90%.
[0076] Another aspect of the present disclosure provides a method for delivering siRNA to the liver in vivo, wherein the MELK-targeting particle of the present disclosure is administered to a subject.
[0077] The MELK-targeting particles and pharmaceutical compositions disclosed herein can reduce the level of MELK mRNA in a cell, a cell population, a tissue or a subject, comprising: administering a therapeutically effective amount of the MELK-targeting particles or pharmaceutical compositions described herein to the subject.
[0078] Delivery can be by administration, injection, implantation, subcutaneous, intravenous, intraperitoneal, intramuscular, transdermal, airway, nasal, oral, rectal, etc.
[0079] In some embodiments, the MELK-targeting particles or pharmaceutical compositions provided by the present disclosure can be administered by injection, for example, intravenous, intramuscular, intradermal, subcutaneous, or intraperitoneal injection.
[0080] Another aspect of the present disclosure provides use of particles targeting MELK in preparing a medicament, wherein the medicament is used for treating liver cancer.
[0081] The present disclosure also provides use of MELK-targeted particles in preparing a sensitizer, wherein the sensitizer is used to enhance the sensitivity of liver cancer cells to radiofrequency ablation. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1A : Schematic diagram of the construction of RGD-LNP-siMELK-Cy5.5.
[0083] Figure 1B : TEM image of LNPs, showing particles with a diameter of 100 nm.
[0084] Figure 1C : Size distribution of LNPs.
[0085] Figure 1D : Electrophoresis analysis of LNP-siRNA with different mass ratios.
[0086] Figure 1E : Cumulative release percentage of siMELK under different pH environments.
[0087] Figure 2A : Representative IF images of LNP uptake by LO2 normal hepatocytes and HCC-LM3 hepatoma cells.
[0088] Figure 2B : Histogram of relative intensity of Cy5.5 in LO2 hepatocytes at different times (n=3).
[0089] Figure 2C : Histogram of relative intensity of Cy5.5 in HCC-LM3 liver cancer cells at different times (n=3).
[0090] Figure 2D : Expression of MELK, FABP5, and actin (housekeeping gene control) in SK-HEP1 and HCC-LM3 cells after different treatments, including CTR, siMELK, LNPs, and LNP-siMELK.
[0091] Figure 2E : Viability of SK-HEP1 and HCC-LM3 cells after different treatments.
[0092] Figure 3A : When LNPs-siMELK-Cy5.5 (represented as siMELK-Cy5.5 in the figure) or naked siMELK-Cy5.5 was applied, the residual percentage of Cy5.5 in serum was detected by fluorescence over time.
[0093] Figure 3B : Fluorescence optical images showed that Cy5.5 accumulated in different tissues when RGD-LNPs or LNPs were applied.
[0094] Figure 3C : Histograms of mean radiation in different organs when RGD-LNPs or LNPs were applied (n=5).
[0095] FIG. 4A to FIG. 4C : Schematic diagram of CCK-8 method for detecting the survival rate of SK-HEP1 (A), HCC-LM3 (B) and Hepa1-6 (C) cells after in vitro inhibition of MELK activation after simulated radiofrequency ablation.
[0096] Figure 5A : Illustration of the animal model showing the different treatments in the five groups.
[0097] Figure 5B : Images of Hepa1-6 tumor tissues isolated when mice were euthanized (n=5).
[0098] Figure 5C : Violin plots show the average weight of five tumors in each group at the time mice were euthanized.
[0099] Figure 5D : Violin plots show the average volume of five tumors in each group at the time mice were euthanized.
[0100] Figure 5E : Monitoring data showed the growth of Hepa1-6 subcutaneous tumors in five groups.
[0101] Fig. 6A : IF images show Ki67, CD8A, GZMA and CD8 in Hepa1-6 tumor tissues.
[0102] Figure 6B : The proportion of Ki67+CD8+T cells in CD8+T cells.
[0103] Figure 6C : The proportion of GZMA+CD8+T cells in CD8+T cells.
[0104] Fig.6D : ELISA showed the concentration of TNF-α in five groups of Hepa1-6 tumor tissues.
[0105] Fig. 6E : ELISA showed the concentration of INF-γ in five groups of Hepa1-6 tumor tissues. DETAILED DESCRIPTION
[0106] Example 1. Preparation of lipid nanoparticles
[0107] The preparation process of lipid nanoparticles is as follows Figure 1A shown.
[0108] 1. Relative molecular weight of each component in lipid nanoparticles:
[0109] Table 1
[0110]
[0111] cRGD: cyclic RGD.
[0112] 2. The amount of the main components in the lipid nanoparticles (by molar ratio):
[0113] DPPC:DOTAP:CHOL:DSPE-PEOz:DSPE-PEG2K-cRGD=
[0114] 10:5:5:2:1 (molar ratio).
[0115] 3. Amount of dye used
[0116] 0.5 mg Cy5.5-NHS (Cy5.5 monosuccinimidyl ester) (the amount of Cy5.5 can be in the range of 1-5% w / w of the total amount of liposomes).
[0117] 4. Grouping (see Table 2):
[0118] LNPs-CRT: cationic liposomes without RGD or siMELK;
[0119] LNPs-siMELK (LNP-siMELK-Cy5.5): cationic liposomes containing siMELK without RGD;
[0120] RGD-LNPs-siMELK (RGD-LNP-siMELK-Cy5.5): cationic liposomes containing RGD and siMELK.
[0121] 5. Specific steps
[0122] (1) Synthesis of lipid nanoparticles by thin film dispersion method: Calculate the corresponding mass according to the molecular weight of Chol, DPPC, DOTAP, DSPE-PEOz, DSPE-PEG2K-cRGD, and Cy5.5 and weigh them accurately. Dissolve them in an organic solvent (chloroform: methanol volume ratio 3:1) according to a certain molar ratio or mass ratio, and dissolve them in an eggplant-shaped bottle by ultrasonic vibration.
[0123] The next group was synthesized (in vivo and in vitro uptake experiments and electrophoresis, etc.), and the reagents were preliminarily quantified.
[0124] Table 2
[0125]
[0126] (2) Synthesis of drug-carrying liposomes: Rotary evaporation: Rotary evaporator at 45-50°C, 100 rpm, 15-20 min. The vent should be closed during use, opened at the end, and then the pressure switch should be turned off, otherwise the solution will be sucked back. After evaporation, a thin film will form on the bottle wall. After spin drying, add 1 ml of nuclease-free water to dissolve it, disperse the mixture evenly through an ultrasonic cleaner, filter it using a liposome extruder (100 nm filter membrane), and store it at 4°C away from light.
[0127] (3) Loading siRNA
[0128] A) Control particles:
[0129] Non-targeting siRNA was added to LNPs-CRT as a control.
[0130] B) Loading siRNA targeting MELK:
[0131] The siRNA powder was briefly centrifuged at 10,000 rpm before use to concentrate it at the bottom of the tube.
[0132] Dissolve siRNA (with amino modification) in RNase inhibitor and RNase-free PBS buffer. Dissolve Cy5.5-NHS ester in DMSO or DMF.
[0133] Slowly add the Cy5.5-NHS ester solution to the siRNA solution while gently mixing. The reaction is carried out at room temperature for 1 hour to overnight.
[0134] After the reaction is complete, unreacted Cy5.5 dye is removed by gel filtration, HPLC or other appropriate purification methods, and the conjugated siRNA-Cy5.5 product is collected and purified.
[0135] Dissolve 1 OD of siRNA-Cy5.5 (1 OD is about 33 μg, about 2.5 nmol) in 66 μL of nuclease-free water. Pipette the corresponding volume according to the experimental requirements, add protamine (siRNA and protamine are calculated by mass ratio. The common mass ratio of siRNA to protamine is between 1:1 and 1:10. As an example, m(siRNA):m(protamine)=1:1 is selected), mix gently, and incubate at room temperature for 10 min.
[0136] Take out the liposome mixture prepared in advance, mix it with an ultrasonic cleaner before use, and leave it at room temperature for 5 minutes. The nanomaterial is prepared and ready for use.
[0137] Example 2. Uptake of LNP by liver cancer cells
[0138] Equal volumes of LNPs-siMELK-Cy5.5 were added to LO2 hepatocytes and HCC-HCC-LM3 hepatoma cells cultured in vitro.
[0139] Over time, liver cancer cells showed a stronger ability to take up LNPs than normal liver cells ( FIG. 2A to FIG. 2C ).
[0140] Example 3. Knockdown of target gene by LNPs-siMELK-Cy5.5
[0141] The MELK knockdown levels in SK-HEP1 and HCC-LM3 cells were examined at the protein level to compare the direct addition of MELK siRNA (ie, naked siMELK-Cy5.5) and LNPs-siMELK-Cy5.5.
[0142] Figure 2D It showed that the MELK knockdown efficiency of LNPs-siMELK-Cy5.5 was significantly higher than that of naked siMELK-Cy5.5, and FABP5 inhibition was also significantly increased.
[0143] The CCK8 assay results also showed that although naked siMELK-Cy5.5 reduced liver cancer cell proliferation and viability, the effect of LNPs-siMELK-Cy5.5 was more significant ( Figure 2E ).
[0144] Example 4. Targeting to liver cancer cells
[0145] The Cy5.5 signal in the serum supernatant further indicated that encapsulation in LNPs made siRNA difficult to eliminate, which partly explained the enhanced antitumor effect of nanoliposome-encapsulated MELK siRNA ( Figure 3A ).
[0146] The tumor targeting of RGD-LNPs-siMELK and LNPs-siMELK was also compared by thermal imaging. It is clear that RGD peptide significantly increased the targeting of LNPs to tumors ( FIG. 3B to FIG. 3C ). TEM and in vitro and in vivo confocal laser scanning microscopy verified that the synthesized RGD-LNPs-siMELK was of good quality, had good targeting to liver cancer cells and tissues, and the MELK interference efficiency reached the expected level, making it suitable for subsequent use.
[0147] Example 5. Combination with RFA therapy
[0148] 1. The liver cancer cells were heated in a 47°C water bath for 10 minutes to construct human liver cancer cell SK-HEP1, highly metastatic human liver cancer cell HCC-LM3 and mouse liver cancer cell Hepa1-6 cell lines that simulated in vitro radiofrequency ablation, and the particles disclosed in the present invention were used to conduct cell proliferation and survival rate experiments.
[0149] MELK knockdown in liver cancer cells can enhance the anti-tumor effect induced by RFA. It was also found that LNPs containing siMELK (LNPs-siMELK-Cy5.5, LNPs-siMELK) inhibited liver cancer cell viability and enhanced tumor cell inhibition at 47°C under exogenous application ( FIG. 4A to FIG. 4C ).
[0150] 2. A subcutaneous tumor-bearing model was established. 6 / 100 μL of Hepa1-6 cells were injected subcutaneously into the inner side of the left lower limb of 8-week-old male C57BL / 6 mice. An 18G bipolar ablation needle was placed in the tumor tissue, and the radiofrequency tail needle was connected to the radiofrequency transmitter. The radiofrequency temperature was set to 60°C, and the radiofrequency ablation was repeated for 2 minutes. A mouse liver cancer postoperative radiofrequency ablation model was constructed and the particles disclosed in the present invention were given for treatment.
[0151] Every three days, siMELK or LNP-siMELK were directly injected into the tail vein of mice, grouped with or without RFA treatment, and mice were sacrificed on day 21 to harvest tumor tissues ( Figure 5A ). RFA or siMELK alone inhibited tumor growth to some extent, including tumor volume, weight and progression rate.
[0152] Surprisingly, LNP-siMELK has a better tumor inhibition effect than siMELK, especially when used in combination with RFA, its tumor inhibition effect is significantly enhanced ( FIG. 5B to FIG. 5E ).
[0153] The CD8+T cells in the tumor tissue were labeled by double-label IF method, and the proliferative CD8+T cells were labeled. The proliferative cells in the LNP-siMELK and RFA combined treatment group were mainly CD8+ cells, while the proliferative cells in the control group were relatively few. After co-labeling with GZMA, it was found that the number of CD8+T cells with killing function in the LNP-siMELK and RFA combined treatment group was significantly higher than that in the control group ( FIG. 6A to FIG. 6C ).
[0154] Subsequently, the levels of cytokines related to immune activation, including TNF-α, INF-γ, IL-2, and IL-12, were quantitatively detected by ELISA. Both RFA and siMELK alone can promote the secretion of TNF-α and INF-γ to a certain extent, but LNPs-siMELK has a stronger effect, especially when used in combination with RFA, which can significantly increase the levels of TNF-α, INF-γ, IL-2, and IL-12 in TME. FIG. 6D to FIG. 6E ).
[0155] The present invention provides LNPs-siMELK-Cy5.5 that uses pH-responsive lipid nanoshells to encapsulate siMELK for radiosensitization, so that siMELK has higher tumor targeting and longer therapeutic effect, and the effect is better when used in combination with RFA, and has the application potential of synergistically enhancing the tumor treatment effect after radiofrequency ablation of liver cancer.
Claims
1. A particle targeting MELK, comprising: siRNA, and Lipid nanoparticles (LNPs); The siRNA is encapsulated in the LNP; The siRNA targets the MELK gene or its expression product; Preferably, the siRNA targets any target site in MELK mRNA that is at least 21 consecutive nucleotides long; The LNP has an L:N ratio of 10:1 to 5:1, preferably 8:
1.
2. The MELK-targeting particle according to claim 1, wherein: The siRNA comprises a sense strand and an antisense strand; The sense strand and the antisense strand form a double-stranded region, and the sense strand and the antisense strand are at least partially reverse complementary; The sense strand is 21 nucleotides long; The antisense strand is 21 nucleotides long; Preferably, the combination of the sense strand and the antisense strand is selected from the following: 1) the sense strand shown in SEQ ID NO: 1 and the antisense strand shown in SEQ ID NO: 2; 2) The sense strand shown in SEQ ID NO:3 and the antisense strand shown in SEQ ID NO:
4.
3. The MELK-targeting particle according to claim 1, wherein: The surface of the LNP carries RGD peptide; Preferably, the RGD peptide is selected from the group consisting of: cRGD, RGD-4C, iRGD and RGD-PEG.
4. The MELK-targeting particle according to claim 1, wherein: The LNP is composed of: DPPC, DOTAP, CHOL, DSPE-PEOz, DSPE-PEG2K-cRGD; The molar fraction of DPPC is 80 to 120, preferably 100; The molar fraction of DOTAP is 40 to 60, preferably 50; The molar fraction of CHOL is 40 to 60, preferably 50; The molar fraction of DSPE-PEOz is 16 to 24, preferably 20; The molar fraction of DSPE-PEG2K-cRGD is 8 to 12, preferably 10.
5. The MELK-targeting particle according to claim 4, wherein: The molar ratio of DPPC, DOTAP, CHOL, DSPE-PEOz, and DSPE-PEG2K-cRGD is 2:1:1:0.4:0.
2.
6. The MELK-targeting particle according to claim 1, further comprising a near-infrared dye, preferably a cyanine dye; The cyanine dye is selected from Cy5.5, Cy7 and ICG; The mass percentage of the cyanine dye in the LNP is 1% to 5%; Preferably, the cyanine dye is Cy5.5; it is selected from: Cy5.5-NHS, Cy5.5-SE, preactivated PE-Cy5.5 maleimide, sulfo-Cyanine5.5 alkyne, sulfonated Cy5.5-azide; most preferably Cy5.5-NHS.
7. The MELK-targeting particle according to claim 1, wherein: The average particle size of the LNP is 80 to 120 nm; preferably 100 nm; Preferably, the average zeta potential of the LNPs is 32 mV.
8. A pharmaceutical composition comprising: The MELK-targeting particle according to any one of claims 1 to 7; Pharmaceutically acceptable carriers, diluents, and / or excipients.
9. Use of the MELK-targeting particle according to any one of claims 1 to 7 in preparing a medicament, wherein the medicament is used to treat liver cancer. 10 . The use according to claim 9 , wherein the MELK-targeting particles are administered in combination with radiofrequency ablation. 11 . Use of the MELK-targeting particle according to any one of claims 1 to 7 in the preparation of a sensitizer, wherein the sensitizer is used to enhance the sensitivity of liver cancer cells to radiofrequency ablation.
